top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
MTU391
15 major types of cancer covering top 10 cancers both in the East and West from 12 anatomic sites. Most of the tumor types have duplicates from different patients with corresponding uninvolved tissues as controls with grading and TNM staging data..
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$213
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
Human
39
39
2.0mm
4um
5
8
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in top 15 cancer types.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 65 | Bladder, urinary | Normal | |||
A02 | F | 39 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
A03 | M | 61 | Bladder, urinary | Transitional cell carcinoma | III | T2N0M0 | |
A04 | F | 34 | Breast | Normal breast | |||
A05 | F | 43 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
A06 | F | 75 | Breast | Invasive ductal carcinoma | III | T3N0M0 | |
A07 | M | 32 | Stomach | Normal stomach | |||
A08 | M | 66 | Stomach | Adenocarcinoma | II | T3N0M0 | |
B01 | M | 47 | Stomach | Adenocarcinoma | III | T3N2M0 | |
B02 | F | 43 | Intestine, colon | Normal colon | |||
B03 | M | 36 | Intestine, colon | Adenocarcinoma | III | T3N1M0 | |
B04 | M | 55 | Intestine, rectum | Adenocarcinoma | I~II | T3N1M0 | |
B05 | M | 30 | Kidney | Normal kidney cortex | |||
B06 | F | 79 | Kidney | Cear cell carcinoma | T1N0M0 | ||
B07 | M | 72 | Kidney | Cear cell carcinoma | T1N0M0 | ||
B08 | M | 35 | Liver | Normal | |||
C01 | M | 59 | Liver | Hepatocellular carcinoma | II | T3N0M0 | |
C02 | M | 19 | Liver | Hepatocellular carcinoma | I~II | T2N0M0 | |
C03 | M | 59 | Lung | Normal | |||
C04 | M | 58 | Lung | Squamous cell carcinoma | II~III | T2N0M0 | |
C05 | F | 40 | Lung | Adenocarcinoma | II~III | T2N0M0 | |
C06 | M | 1.3 | Lymph node | Reactive | |||
C07 | M | 40 | Lymph node | Lymphoma, Hodgkin lymphoma | |||
C08 | M | 42 | Lymph node, axillary | Lymphoma, non-Hodgkin B cell lymphoma | |||
D01 | F | 23 | Ovary | Normal | |||
D02 | F | 43 | Ovary | Mucinous cystadenocarcinoma | III | T2N0M0 | |
D03 | F | 58 | Ovary | Endometrioid adenocarcinoma | III | T2N0M0 | |
D04 | F | 58 | Pancreas | Normal | |||
D05 | F | 49 | Pancreas | Adenocarcinoma | II | T3N1M1 | |
D06 | M | 66 | Pancreas | Adenocarcinoma | II~III | T3N0M0 | |
D07 | M | 73 | Prostate | Normal | |||
D08 | M | 63 | Prostate | Adenocarcinoma | III | T3N0M0 | |
E01 | M | 60 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E02 | M | 53 | Skin, penis | Normal skin | |||
E03 | M | 34 | Skin, penis | Squamous cell carcinoma | I | T1N0M0 | |
E04 | M | 73 | Skin | Melanoma | |||
E05 | F | 46 | Uterus | Normal | |||
E06 | F | 41 | Uterus, cervix | Squamous cell carcinoma | I~II | T1N1M0 | |
E07 | F | 53 | Uterus, endometrium | Adenocarcinoma | II~III | T1N1M0 | |
null |
bottom of page